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Background: Epidermal growth factor receptor (EGFR) is suggested to predict the radiosensitivity and/or prognosis
of human esophageal squamous cell carcinoma (ESCC). The objective of this study was to investigate the efficacy of
Nimotuzumab (an anti-EGFR monoclonal antibody) on ESCC radiotherapy (RT) and underlying mechanisms.
Methods: Nimotuzumab was administrated to 2 ESCC cell lines KYSE30 and TE-1 treated with RT. Cell growth,
colony formation and apoptosis were used to measure anti-proliferation effects. The method of RNA interference
was used to investigate the role of insulin-like growth factor binding protein-3 (IGFBP-3) in ESCC cells
radiosensitivity treated with Nimotuzumab. In vivo effect of Nimotuzumab on ESCC radiotherapy was done using a
mouse xenograft model.
Results: Nimotuzumab enhanced radiation response of KYSE30 cells (with high EGFR expression) in vitro, as
evidenced by increased radiation-inhibited cell growth and colony formation and radiation-mediated apoptosis.
Mechanism study revealed that Nimotuzumab inhibited phosphorylated EGFR (p-EGFR) induced by EGF in KYSE30
cells. In addition, knockdown of IGFBP-3 by short hairpin RNA significantly reduced KYSE30 cells radiosensitivity
(P<0.05), and even after the administration of Nimotuzumab, the RT response of IGFBP-3 silenced KYSE30 cells was
not enhanced (P>0.05). In KYSE30 cell xenografts, Nimotuzumab combined with radiation led to significant tumor
growth delay, compared with that of radiation alone (P=0.029), and also with IGFBP-3 up-regulation in tumor tissue.
Conclusions: Nimotuzumab could enhance the RT effect of ESCC cells with a functional active EGFR pathway. In
particular, the increased ESCC radiosensitivity by Nimotuzumab might be dependent on the up-regulation of
IGFBP-3 through EGFR-dependent pathway.
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Esophageal cancer is an aggressive cancer constituting the
sixth cause of cancer-related deaths worldwide [1]. The
main histological type is squamous cell carcinoma (SCC)
in East Asian. Despite ongoing research in the treatment of
ESCC, the prognosis for patient long-term survival remains
poor. Surgery alone for locally advanced disease results in
a 5-year survival rate of only 20-25%. Although the* Correspondence: xiedan@sysucc.org.cn; liumengzhong@126.com
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reproduction in any medium, provided the oraddition of combined modality strategies of pre- or post-
operative chemoradiotherapy is reported to improve the
5-year survival rates of 10-15% [2,3], the therapeutic tox-
icity remains to be a big problem to overcome. Therefore,
an efficacious therapy with minimal toxicity is still urgently
needed. Along with a better understanding of molecular
pathways of esophageal carcinogenesis, the focus of recent
study has shifted toward testing newer agents that target
specific molecular abnormalities known to occur in ESCC.
In preclinical studies involving various cancer models,
including ESCC, overexpression of EGFR has been found
to contribute to epithelial cell proliferation, differentiation,
and migration [4,5] and had an inverse relationship totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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EGFR has been shown to correlate with lower tumor control
rates after irradiation in several studies [8,9]. Recently, com-
bination of radiotherapy and EGFR inhibitors was reported
to improve local tumor control compared to irradiation
alone, but it is also true that conflicting results exist [10,11].
Nimotuzumab is a humanized anti-EGFR monoclonal
antibody (mAb) that binds to the extracellular domain of
the EGFR and inhibits EGF binding [12]. In a preclinical
study, Nimotuzumab demonstrated marked antiprolifera-
tive, proapoptotic, and antiangiogenic effects in tumors that
overexpress EGFR [13]. Now, Nimotuzumab has been
approved in several countries for the treatment of head and
neck tumors [14] and glioma [15], and is in clinical trials
for various tumor types including head and neck tumors,
colorectal, glioma (pediatric and adult), pancreatic, prostate,
non-small cell lung, cervical, and breast cancer [14-17].
And clinically, Nimotuzumab has shown high safety and
low toxicity without severe skin and mucosa toxicities com-
monly associated with other EGFR targeting antibodies
[18]. In esophageal cancer, EGFR overexpression by immu-
nohistochemistry or gene amplification by fluorescent in
situ hybridization (FISH) analysis occurs in 30-90% of
tumors. Generally, EGFR overexpression is more common
in ESCC than in esophageal adenocarcinoma [19]. In our
previous study, we found that Nimotuzumab could increase
ESCC chemosensitivity to DDP by upregulating IGFBP-3
expression through EGFR-dependent pathway in vitro [20].
However, whether or not Nimotuzumab can radiosensitize
ESCC both in vitro and in vivo with different expression
levels of EGFR is unknown. In the present study, we there-
fore investigated the efficacy of the anti-epidermal EGFR
mAb, Nimotuzumab, on ESCC cells radiotherapy and its
potential underlying mechanisms in vitro and in vivo.
Methods
Cell lines and reagents
The human ESCC cell lines, KYSE30 and TE-1, were
obtained from the Cell Bank of the Chinese Academy of
Sciences (Shanghai, China). Both cell lines were cultured
in RPMI 1640 medium (Invitrogen, Carlsbad, CA) sup-
plemented with 10% fetal bovine serum (Bioind, Kibbutz
Beit, Israel) in a humidified 5% CO2 atmosphere at 37°C.
In previous study, we have confirmed there is a higher
level of EGFR protein expression in KYSE30 cells com-
pared with that in TE-1 cells at baseline by Western blot
and immunocytochemical staining analysis [20]. Nimo-
tuzumab was provided by Biotech Pharmaceuticals Co.,
Ltd. (Beijing, China). All the other chemical reagents
and solvent were from Sigma-Aldrich (St. Louis, MO).
Measurement of cell toxicity
KYSE30 and TE-1 cells were plated in 96-well plates at a
density of 2,000-3,000 cells/well and incubated for 72 hourswith indicated concentrations (6.25 μg/mL, 12.5 μg/mL, 25
μg/mL, 50 μg/mL, 100 μg/mL, 200 μg/mL) of Nimotuzu-
mab alone or combined with various doses of X-ray with
a 160 KV X-irradiator (Rad Source Technologies, Inc.
Suwanee, GA) at a rate of approximately 8.7 Gy/minute.
The cells were then incubated for 4 hours in medium con-
taining 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) and lysed in dimethylsulphoxide (DMSO).
This procedure was performed as previously described [21].
The conversion of MTT to formazan by metabolically vi-
able cells was monitored using a 96-well microtiter plate
reader at an absorbance of 570 nm.
Clonogenic assay
Cells were supplemented with 1% fetal bovine serum in
the absence or presence of Nimotuzumab. After incuba-
tion for 24 hours, the cells were exposed to various doses
of X-ray. The cells were cultured in drug-free medium
with 10% fetal bovine serum for 10–14 days, then fixed
and stained with crystal violet and counted manually. Col-
onies containing more than 50 cells were counted. The
surviving fractions were determined as ratios of the plating
efficiencies (PE = counted colonies/seeded cells × 100) of
the irradiated cells to the non-irradiated cells. The DMF10
was established to analyze the effects of Nimotuzumab on
the radiosensitivity of ESCC cells (DMF10 = radiation dose
untreated cells/radiation dose treated cells). To fit the data
a linear quadratic model lnS = −(αD + βD2) was applied,
using origin 7.5.
Western blot analysis
This procedure has been previously described [20,22]. The
cells were lysed using a 50 nM Tris (pH7.5), 150 mM
NaCl, and 0.5% NP-40 solution on ice. Fifty micrograms
of total protein from each sample was resolved on a 12%
bis–tris gel with MOPs running buffer and transferred to
nitrocellulose membranes. The blots were probed with
various antibodies, including anti-EGFR, p-EGFR-1068
and Caspase-3 (Cell Signaling Technology, Beverly, MA),
IGFBP-3 (Santa Cruz Biotech, CA).
Apoptosis assays
The ESCC cells undergoing apoptosis were distinguished
from live and necrotic cells by the use of annexin-V and
propidium iodide (PI) staining using Apoptosis Detec-
tion Kit (Invitrogen). Briefly, ESCC cells were treated
with Nimotuzumab (100 μg/mL, 24 hours) and/or irra-
diated with either 2Gy or 10Gy, and harvested after 48
hours post-irradiation. Aliquots of 105 cells were incu-
bated with annexin-V/PI for 15 minutes at room
temperature. Cells were then analyzed by means of flow
cytometry using a two-color fluorescence activated cell
sorting (FACS) analysis (Beckman Coulter, cytomics FC
500, CA).
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(shRNA)
A previously constructed lentivirus transfer vector, which
encoded shRNA targeting IGFBP-3 and can efficiently si-
lence endogenous IGFBP-3 in cancer cells was utilized
[23]. Briefly, lentiviral pGIPZ vectors carrying shRNA
directed against human IGFBP-3 (V2LHS_111628 and
225584) and a non-silencing scramble control sequence
(RHS4346) along with green fluorescent protein (Open
Biosystems, Huntsville, AL) were used. Three days after
Lentiviral pGIPZ vectors infection, the ESCC cells were
passaged and selected with geneticin (400 μg/ml; Invitro-
gen, Carlsbad, CA) for 3 weeks for resistant colonies.
Geneticin-resistant clones were harvested and subjected
to Western blot analysis to examine the knocking down
efficiency of IGFBP-3 by lentivirus shRNA.
Xenograft models and therapy
Animal experiments were conducted in accordance with
“Guidelines for the Welfare of Animals in Experimental
Neoplasia”. KYSE30, 3×106 or TE-1, 1×107 cells were
injected subcutaneously in the right hind limbs of female
BALB/c nude mice (4–5 weeks old). Treatment was
initiated when tumors in each group achieved an average
volume of approximately 170-200 mm3 (about 10–14
days). And then the mice were randomized into the fol-
lowing three groups: control, radiation alone (8Gy × 1),
and Nimotuzumab (a single dose of 1.0 mg per mouse)
combined with radiation(N = 6 per group). Mice in the
control and radiation alone groups were injected with
physiological saline. Radiation began 6 hours after drug
treatment. After 4 weeks, mice were sacrificed and
tumors were resected and weighed. Tumors were mea-
sured at regular 3-days intervals and tumor volume was
determined by caliper measurement of tumor length (L)
and width (W) according to the formula LW2/2.
Immunohistochemical analysis
This procedure was performed as previously described
[24]. The tumors slides of xenograft were deparaffinized in
xylene, rehydrated through graded alcohol, immersed in
3% hydrogen peroxide for 10 minutes to block endogenous
peroxidase activity, and antigen retrieved by pressure cook-
ing for 3 minutes in citrate buffer (pH = 6). To block non-
specific binding, the slides were pre-incubated with 10%
normal goat serum at room temperature for 30 minutes.
Subsequently, the slides were incubated overnight at 4°C in
a moist chamber with mouse monoclonal antibody anti-p-
EGFR (Cell Signaling Technology; 1:1600 dilution) and
rabbit polyclonal antibody anti-IGFBP-3 (Santa Cruz Bio-
technology; 1:100 dilution). The slides were sequentially
incubated with a secondary antibody (Envision; Dako,
Glostrup, Denmark) for 1 hour at room temperature, and
stained with DAB (3,3-diaminobenzidine). Finally, thesections were counterstained with Mayer’s hematoxylin,
dehydrated and mounted. A negative control was obtained
by replacing the primary antibody with a normal murine
or rabbit IgG. Known immunostaining-positive slides were
used as positive controls.
Statistical analysis
All descriptive statistics, including mean ± SD, were per-
formed. Unpaired Student’s t-test was used to evaluate
differences between the control group and each treat-
ment group in all in vitro and in vivo studies performed,
with the resultant P value representing a two-sided test
of statistical significance. SPSS 13.0 software (SPSS, Inc.,
Chicago, IL) was used for statistical analyses with a P value
of < 0.05 considered statistically significant.
Results
Nimotuzumab enhanced radiation response of ESCC cells
with high expression of EGFR in vitro
Firstly, we examined weather Nimotuzumab has
chemotherapeutic-induced toxic effects in ESCC cells
in vitro. We found that Nimotuzumab was not toxic to
either KYSE30 or TE-1 cell line, even when they were
treated with 200 μg/mL of Nimotuzumab for 72 hours
(P > 0.05), as determined by the MTT assay (Additional
file 1: Figure S1). Next, we tested whether or not Nimo-
tuzumab enhanced ESCC cells sensitivity to radiother-
apy in vitro by MTT assay. KYSE30 and TE-1 cells
were treated with various doses of RT in the presence
of different concentrations of Nimotuzumab. The results
showed that compared to treatment with RT alone, com-
bination of RT and Nimotuzumab resulted in a significant
higher level of cell death in KYSE30 cells (P = 0.01;
Additional file 2: Figure S2A), but not significant in
TE-1 cells (the cell line with low levels of EGFR, P =
0.087; see Additional file 2: Figure S2B). Further clono-
genic assays confirmed the above results, in which the
DMF10 (dose-modifying factor at a 10% survival level)
presented in the experiment were 1.68 (P = 0.01) for
the KYSE30, whereas Nimotuzumab had no effect on
radiosensitivity of TE-1 cells (DMF10 was 0.98, P = 0.2)
(Figure 1a and b).
In our study, the levels of cell apoptosis were further
examined in ESCC cells treated with RT before and after
Nimotuzumab treatment. In KYSE30 cells, we observed
that the percentage of positive cells for annexin-V/PI sig-
nificantly increased in combination treatment group as
compared to that in RT alone group (Figure 1c and
Additional file 3: Figure S3A). However, the similar re-
sult was not observed in TE-1 cells (Figure 1c and
Additional file 3: Figure S3B). In addition, we examined
apoptosis related caspase-3 activation in KYSE30 cells.
We found that caspase-3 was further activated in 72 hours
after exposure to Nimotuzumab and RT (Figure 1d).
Figure 1 Nimotuzumab enhanced the sensitivities of EGFR overexpressed ESCC cells to RT in vitro. (a and b) KYSE30 and TE-1 cells were
incubated with or without Nimotuzumab (100 μg/mL) for 24 hours, and exposed to the indicated doses of RT. The colonies were stained and
counted, and survival curves were constructed from three independent experiments. N = 3, bars, ± SD. The result is representative at 6 Gy of RT
dosage. (c) KYSE30 and TE-1 cells were treated with RT (2 Gy, 10 Gy) in presence or absence of Nimotuzumab (100 μg/mL) for 48 hours. The
control, RT and combination treatment groups were collected for staining with annexin-V/PI. The samples with a statistically significant difference
compared with the groups as indicated (N = 3, bars, ± SD.) (d) Cell lysates were subjected to immunoblot with caspase-3-specific antibody for
cleavage of caspase-3.
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overexpressing ESCC cells
To investigate potential mechanisms of Nimotuzumab
in the promotion of ESCC cells radiosensitivity, we first
studied whether or not Nimotuzumab could influence
the levels of EGFR in ESCC cells. Our results showed
that in the levels of EGFR under identical culture condi-
tion (with 10% fetal bovine serum), Nimotuzumab did
not influence the total levels of EGFR in either EGFR
overexpressing KYSE30 or EGFR low-expressing TE-1
cell line. However, Nimotuzumab did down-regulate the
levels of p-EGFR in KYSE30 cells. In TE-1 cells, owing
to the presence of p-EGFR is not detectable in the con-
trol cells (without adding Nimotuzumab), the effect of
p-EGFR downregulation cannot be observed in cellstreated with Nimotuzumab (Figure 2). We hypothesized
that the multiple low-concentration cytokines in fetal
bovine serum could only activate EGFR pathway in
EGFR high-expression KYSE30 cells, however, this effect
was not observed in TE-1 cells due to low-expression
EGFR. These results revealed that Nimotuzumab down-
regulated the levels of EGFR phosphorylation in EGFR
overexpressing ESCC cells.
IGFBP-3 up-regulation is involved in nimotuzumab-
enhanced radiosensitivity of ESCC cells
Recent studies documented that IGFBP-3, one of EGFR
downstream targets, plays an important role in modula-
tion of radiosensitivity of different human cancers [25],
and EGF could down-regulate IGFBP-3 expression in
Figure 2 Modulation of EGFR and p-EGFR expression in ESCC
cells by Nimotuzumab. Both KYSE30 and TE-1 cell lines were
cultured with 0, 100 and 200 μg/mL Nimotuzumab for 72 hours in
medium containing 10% FBS. Western blot analysis was performed
to examine the expression levels of EGFR and p-EGFR. Nimotuzumab
did not influence the levels of EGFR in both cells, but it down-
regulated the expression of p-EGFR in KYSE30 cells with
overexpression of EGFR. Representative result was shown of triplicate
experiments.
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investigated whether Nimotuzumab inhibited EGF-induced
EGFR phosphorylation, and consequently down-regulated
IGFBP-3 in ESCC cells. To investigate the effect of EGF on
ESCC cells, KYSE30 and TE-1 cells were deprived of serum
overnight. As demonstrated in Figure 3a, EGFR phosphor-
ylation could not be detected without the addition of EGF.
Nimotuzumab inhibited the levels of EGFR phosphoryl-
ation induced by EGF (100 ng/mL) in a dose-dependent
manner, and concurrent with an up-regulated expres-
sion of IGFBP-3 in EGFR overexpressing KYSE30 cells
(Figure 3a, left). But this effect was not observed in
EGFR low-expressing TE-1 cells (Figure 3a, right). To
further investigate the effect of IGFBP-3 in the process
of Nimotuzumab modulating of ESCC cells radiosensi-
tivity, the expression levels of IGFBP-3 in KYSE30 cell
line were first knocked down by a specific shRNA tar-
geting IGFBP-3 gene (Figure 3b). Next, the IGFBP-3-
silenced and non-silenced KYSE30 cells were exposed
to Nimotuzumab (100 μg/mL), 10Gy X-irradiation or
combination, and maintained for 72 hours in culture.
Apoptosis and clonogenic assay demonstrated that com-
pared to that in non-silenced KYSE30 cells, the radiosensi-
tivity in IGFBP-3-silenced KYSE30 cells were significantly
inhibited (Figure 3c and Additional file 4: Figure S4A),
and furthermore, even after the administration of Nimotu-
zumab, the radiotherapy response of IGFBP-3 silenced
KYSE30 cells was not enhanced (P > 0.05, Figure 3c and
Additional file 4: Figure S4B). These results provided evi-
dences that the level of IGFBP-3 is responsible, at least
partly, to the enhanced radiosensitivity by Nimotuzumab
in ESCC cells with overexpression of EGFR.Nimotuzumab increased IGFBP-3 expression and
radiosensitivity of ESCC cells with high expression of
EGFR in vivo
To test the effects of Nimotuzumab on ESCC cells radio-
sensitivity in vivo, we further constructed ESCC xenograft
models by injecting tumor cells subcutaneously in BALB/c
nude mice. In vitro, radiotherapy alone did not induce
up-regulation of IGFBP-3 expression in KYSE30 cells
(Additional file 5: Figure S5A). As shown in Figure 4a, ex-
pression levels of p-EGFR and IGFBP-3 in tumors slides
of KYSE30 cell xenografts after RT with or without Nimo-
tuzumab treatment were examined using immunohisto-
chemical analysis. Expression of p-EGFR and IGFBP-3 in
tumors was quantified by counting positive cells in 3 fields
from 3 mice. Same as the results in vitro, after Nimotuzu-
mab administration, the level of EGFR phosphorylation
was inhibited in KYSE30 cell xenograft tumors, concur-
rent with IGFBP-3 up-regulation. In KYSE30 xenografts of
nude mice, there was a significant increase in tumor
growth delay in animals treated with combination of
Nimotuzumab and RT, compared with that treated with
radiation alone (P = 0.029; Figure 4b). However, in TE-1
xenografts, we observed that tumor growth was also
inhibited by radiation, but this radiotherapy effect could
not be enhanced by concurrent treatment of Nimotuzu-
mab (P = 0.672; Additional file 5: Figure S5B).
Discussion
Clinically, RT is one of the most important therapeutic
methods for ESCC, especially for those unresectable ones.
Thus, new strategies that could enhance ESCC RT response
and have no further therapeutic toxicities on normal tissues
have been long-time needed. Previous studies reported that
alteration in the expression and activity of growth factor
receptors could not only directly perturb growth regulation,
but also affect the sensitivity of cancer cells to various cyto-
toxic treatments, including RT [28,29]. Several groups iden-
tified that EGFR inhibitors could improve RT response and
local control of human tumors, providing a kind of add-
itional agents in anti-cancer therapy [10,11].
Nimotuzumab is a humanized IgG1 isotype monoclo-
nal antibody of EGFR, which requires bivalent binding
(i.e., binding with both antibody arms to two targets
simultaneously) for stable attachment to cellular surface.
Recently, it was reported that Nimotuzumab could sub-
stantially improve the radiosensitivity of brain tumor
[30] and non-small cell lung cancer [31] cells with high
or moderate levels of EGFR. In the present study, we
determined to investigate the impact of Nimotuzumab
on ESCC RT response and underling mechanisms. Our
results demonstrated that although Nimotuzumab alone
failed to inhibit ESCC cells growth, we did observe as
well that Nimotuzumab dramatically enhanced radiation
response of ESCC KYSE30 cell line (the cells with
Figure 3 The levels of IGFBP-3 are responsible to Nimotuzumab-enhanced radiosensitivity of EGFR overexpressing ESCC cells. (a)
KYSE30 and TE-1 cells were deprived of serum overnight and then incubated first for 3 hours with or without Nimotuzumab and then for an
additional 15 minutes in the additional absence or presence of EGF (100 ng/mL). Cell lysates were evaluated for IGFBP-3, phosphorylated and
total EGFR by Western blot. (b) IGFBP-3 silenced KYSE30 cells were harvested after 72 hours exposure to Nimotuzumab (100 μg/mL) or not. The
expression levels of IGFBP-3 in control (non-silenced cells), IGFBP-3-silenced and Nimotuzumab-treated IGFBP-3-silenced cells were determined by
Western blot. The experiments were performed in triplicate. (c) IGFBP-3-silenced KYSE30 cells were treated with RT (10 Gy) in presence or absence
of Nimotuzumab (100 μg/mL) for 72 hours. All cells were collected for staining with annexin-V/PI, and cell death was measured by flow
cytometry. In RT experiment, the radiosensitivity of KYSE30 cells was significantly inhibited after IGFBP-3 silence, and the cell death rates were
reduced from 46.2 ± 2.1% to 25.9 ± 3.1% (P < 0.05). After the administration of Nimotuzumab, the RT response of IGFBP-3-silenced KYSE30 cells
was not enhanced (the cell death rate was 28.6 ± 2.8%) (P > 0.05). The experiments were performed in triplicate.
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evidenced by increased radiation-inhibited cell growth
and colony formation and radiation-mediated apoptosis.
But similar results were not found in EGFR low-
expressed ESCC cell line TE-1. These results revealed
that Nimotuzumab only improved the radiosensitivity of
ESCC cells with high expression of EGFR, suggesting a
potential EGFR-dependent synergistic cytotoxicity of
Nimotuzumab when combined with RT.Previous reports documented that the anti-tumor effect
of certain EGFR-specific mAbs is due to inhibition of lig-
and binding to EGFR and consequent inhibition of EGFR
activation [32,33]. Nimotuzumab was identified only se-
lectively binds to tumor cells that express moderate to
high levels of EGFR [18]. To investigate the potential
mechanisms of Nimotuzumab on promoting radiosensi-
tivity of ESCC cells with high-level of EGFR, we first
examined expression levels of EGFR and phosphorylated
Figure 4 Effects of Nimotuzumab on the response of KYSE30 ESCC xenografts to RT. (a) Representative KYSE30 cell xenografts in RT
treatment and RT + Nimotuzumab treatment groups. p-EGFR and IGFBP-3 expressions of KYSE30 cell xenograft tumors were examined by IHC.
p-EGFR was positively stained in the majority of RT-treated KYSE30 cells of xenograft, while most cells had negative expression of IGFBP-3. In RT +
Nimotuzumab-treated KYSE30 cell xenograft tumor, most tumor cells showed negative expression of pEGFR, while the majority of cells was
positively stained with IGFBP-3 (100×). (b) KYSE30 cells were injected subcutaneously in athymic nude mice. Treatment was initiated when
tumors in each group (N = 6) achieved an average volume of approximately 170–200 mm3. The mice were randomized into three groups:
control, radiation alone (8Gy × 1), and Nimotuzumab (a single dose of 1.0 mg per mouse) combined with radiation. Tumor volume was
determined at the indicated time points thereafter.
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administration of Nimotuzumab in ESCC cells. Our
results showed that Nimotuzumab treatment alone did
not result in any changes of the total EGFR levels in both
EGFR overexpressed KYSE30 and EGFR low-expressed
TE-1 ESCC cell lines. However, Nimotuzumab could
down-regulate the levels of p-EGFR in KYSE30 cells. In
TE-1 cells, in which the basic levels of EGFR were low and
p-EGFR was not detected, the effect of p-EGFR downre-
gulation cannot be observed in cells treated with Nimotu-
zumab. Furthermore, during the stimulation of EGF in
both cells, we examined that the EGF-induced levels of
p-EGFR in KYSE30 cells were dramatically inhibited by
Nimotuzumab in a dose-dependent manner. But this
down-regulation effect of p-EGFR by Nimotuzumab was
not observed in TE-1 cell line. These observations clearly
demonstrated that Nimotuzumab blocked the activation
of EGFR in EGFR-overexpressed ESCC cells. Since previ-
ous studies documented that EGF-induced EGFR activa-
tion could decrease IGFBP-3 protein levels in ESCC TE-2
and TE-7 cell lines [27] and IGFBP-3 has been suggested
as a key marker of radiosensitivity that enhances the sus-
ceptibility of ESCC to RT [25], in our study, we furtherexamined the levels of IGFBP-3 in EGF-treated KYSE30
and TE-1 cell lines before and after Nimotuzumab admin-
istration. As anticipated, the treatment of Nimotuzumab
could up-regulated the levels of IGFBP-3 in EGF-treated
KYSE30 cells, concurrent with the decreased level of
p-EGFR both in vitro and in vivo. Also, this phenomenon
was not observed in EGF-treated TE-1 cell line. These
data, collectively, suggested that Nimotuzumab might up-
regulates IGFBP-3 expression in EGFR-overexpressed
ESCC cells by suppressing the activation of EGFR.
IGFBP-3, a member of the IGFBP family, is the major
carrier protein for insulin-like growth factors (IGF)-I
or IGF-II in circulation [34,35]. Depending on the experi-
mental context, IGFBP-3 has been shown to possess
growth-stimulatory, antiproliferative, or proapoptotic activ-
ities in vitro [36,37]. In addition, IGFBP-3 has also been
identified as a gene that is most highly up-regulated in
EGFR-overexpressing esophageal cancer cell lines and pri-
mary esophageal tumors [26]. In our previous work, we
have demonstrated that IGFBP-3 upregulation after Nimo-
tuzumab administration involved in ESCC cells chemosen-
sitivity to DDP [20]. To determine if IGFBP-3 participates
in Nimotuzumab-enhanced radiosensitivity of ESCC cells
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levels of IGFBP-3 in KYSE30 cells by specific shRNA
against IGFBP-3 gene and found that silence of IGFBP-3
dramatically reduced ESCC cell radiosensitivity. Further-
more, even after the treatment of Nimotuzumab, the radio-
sensitivity of IGFBP-3-silenced KYSE30 cells was almost
not enhanced. These results provided evidences that the
level of IGFBP-3 in EGFR-overexpressing ESCC cells is re-
sponsible, at least in part, for the increased radiosensitivity
by Nimotuzumab. Krause and colleagues previously sug-
gested that IGFBP-3 is a novel EGFR downstream target
molecule in primary and immortalized human esophageal
epithelial cells, and moreover, EGF could suppress IGFBP-
3 expression through activation of MAPK in an EGFR-
tyrosine kinase-dependent manner [27]. These data, taken
together, prompt us to hypothesize that Nimotuzumab
might up-regulate IGFBP-3 expression through EGFR-
dependent pathway to enhance the radiosensitivity of
ESCC cells. Clearly, further works are needed to clarify the
regulation mechanisms of IGFBP-3 in ESCC and confirm
our hypothesis in detail.
It is well known that, in the United States and Western
countries, there has been a dramatic rise in the incidence of
esophageal adenocarcinoma to equal or exceed the inci-
dence of ESCC [38]. Therefore, one limitation of the current
study is no esophageal adenocarcinoma cell lines are investi-
gated. Another limitation of this study is only 2 ESCC cell
lines are studied. In order to minimize the bias on the study
results, we have taken a series of effective measures such as
a panel of EGFR high and EGFR low ESCC cell lines and
adenocarcinoma cell lines used in further study.Conclusions
In summary, ours results demonstrate, for the first time,
that Nimotuzumab enhanced the anti-tumor efficacy of
radiation in EGFR high-expression ESCC cells both
in vitro and in vivo. Mechanism studies, as provided in
this report, suggest that the enhanced radiotherapy effect
by Nimotuzumab in EGFR high-expression ESCC cells
might be dependent on the up-regulated expression of
IGFBP-3 through EGFR-dependent pathway.Additional files
Additional file 1: Figure S1. KYSE30 and TE-1 cells were plated in 96-
well plates at a density of 2,000-3,000cells/well and incubated for 72
hours with indicated concentrations (6.25 μg/mL, 12.5 μg/mL, 25 μg/mL,
50 μg/mL, 100 μg/mL, 200 μg/mL) of Nimotuzumab. The viable cells
were examined by MTT assay.
Additional file 2: Figure S2. The percentages of viable ESCC cells
cultured with Nimotuzumab or combination with RT at the indicated
concentrations for 72 hours by MTT assay. Combination of RT and
Nimotuzumab resulted in a significant higher level of cell death in
KYSE30 cells (P=0.01; A), but not significant in TE-1 cells (P=0.087; B)Additional file 3: Figure S3. KYSE30 and TE-1 cells were treated with
RT (2Gy, 10Gy) in presence or absence of Nimotuzumab (100 μg/mL) for
48 hours. The control, RT and combination treatment groups were
collected for staining with annexin-V/PI to examine apoptosis rates. The
samples with a statistically significant difference compared with the
groups as indicated in KYSE30 cells. The experiments were performed in
triplicate.
Additional file 4: Figure S4. Knockdown of IGFBP-3 decreases
sensitivity of KYSE30 cells to radiation. (A) IGFBP-3-silenced KYSE30 cells
were incubated with or without Nimotuzumab (100 μg/mL) for 24 hours,
and cultured in drug-free medium with 10% fetal bovine serum for 10–
14 days. The colonies were stained and counted, and the result is
representative at 6Gy of RT dosage. (B) KYSE30 cells survival were tested
in 6 groups of control, control scrambled ShRNA, ShRNA, RT, ShRNA+RT
and ShRNA+RT+Nimotuzumab by MTT assay.
Additional file 5: Figure S5. (A) In vitro, radiotherapy alone did not
induce up-regulation of IGFBP-3 expression in KYSE30 cells. (B) Effects of
Nimotuzumab on the response of TE-1 ESCC xenografts to RT. TE-1 cells
were injected subcutaneously in athymic nude mice. Treatment was
initiated when tumors in each group (n=6) achieved an average volume
of approximately 170–200 mm3. The mice were randomized into three
groups: control, radiation alone (8Gy×1), and Nimotuzumab (a single
dose of 1.0mg per mouse) combined with radiation. Tumor volume was
determined at the indicated time points thereafter.
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